Overview

Effect of Entecavir Treatment on Regression and Disease Outcome in HBV-induced Liver Fibrosis and Cirrhosis Patients

Status:
Active, not recruiting

Trial end date:
2025-12-01

Target enrollment:

Participant gender:

Summary

Patients who have completed 2 years follow-up of the past National 12th Five-Year Major Project on Infectious Diseases will receive another 8 years treatment with entecavir (10 years in total). Collect serology, imaging, and other clinical data to evaluate the incidence and mortality of decompensated cirrhosis and hepatocellular carcinoma. Understand the effects of long-term antiviral therapy on HBV-induced liver fibrosis/cirrhosis.

Phase:

Phase 4

Details

Lead Sponsor:

Beijing Friendship Hospital

Collaborators:

Affiliated Hospital of Yanbian University
Beijing YouAn Hospital
Fudan University
Nanfang Hospital of Southern Medical University
Peking University People's Hospital
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai Public Health Clinical Center

Treatments:

Entecavir